Log in

Relevant bibliographies by topics / Dose intensity / Journal articles

To see the other types of publications on this topic, follow the link: Dose intensity.

Journal articles on the topic 'Dose intensity'

Author: Grafiati

Published: 9 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Dose intensity.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ozols, R. F., J. T. Thigpen, J. Dauplat, et al. "Dose intensity." Annals of Oncology 4 (1993): S49—S56. http://dx.doi.org/10.1093/annonc/4.suppl_4.s49.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

SURBONE, ANTONELLA, and VINCENT T. DeVITA. "Dose Intensity." Annals of the New York Academy of Sciences 698, no. 1 Breast Cancer (1993): 279–88. http://dx.doi.org/10.1111/j.1749-6632.1993.tb17219.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Coldman, A. J., and C. M. Coppin. "Calculating dose intensity." Journal of Clinical Oncology 9, no. 9 (1991): 1713–14. http://dx.doi.org/10.1200/jco.1991.9.9.1713.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Piccart, M. J., L. Biganzoli, and A. Di Leo. "S34 Dose intensity and dose density." European Journal of Cancer 34 (February 1998): S8. http://dx.doi.org/10.1016/s0959-8049(97)89207-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Portlock, C. S. "Dose density and dose intensity: where does CHOP go from here?" Annals of Oncology 13, no. 9 (2002): 1329–30. http://dx.doi.org/10.1093/annonc/mdf238.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Tonkin, Katia, and Ian Tannock. "Dose Intensity in Chemotherapy." Journal of Clinical Oncology 3, no. 6 (1985): 891. http://dx.doi.org/10.1200/jco.1985.3.6.891.

Full text

Abstract:

To the Editor: In a recent article, Hryniuk and Bush have established a strong correlation between dose intensity of CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy, and the rate of tumor response in patients with metastatic breast cancer. They also observed a significant correlation between rate of tumor response and median survival time (r = .66, P < .001). The authors were careful to avoid the conclusion that there was a direct correlation between dose intensity and median survival, but it is surprising that they did not examine this more important relationship directly

APA, Harvard, Vancouver, ISO, and other styles

7

Hryniak, William. "Dose Intensity…and Beyond." Cancer Investigation 22, no. 4 (2004): 648–49. http://dx.doi.org/10.1081/cnv-200027172.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Meyer, R., M. Goodyear, and W. Hryniuk. "Dose intensity and lymphoma." Journal of Clinical Oncology 9, no. 8 (1991): 1511. http://dx.doi.org/10.1200/jco.1991.9.8.1511.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Coldman, Andrew J., Christopher M. L. Coppin, and James H. Goldie. "Models for dose intensity." Mathematical Biosciences 92, no. 1 (1988): 97–113. http://dx.doi.org/10.1016/0025-5564(88)90007-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Gianni, A. M., and M. J. Piccart. "Optimising chemotherapy dose density and dose intensity." European Journal of Cancer 36 (April 2000): 1–3. http://dx.doi.org/10.1016/s0959-8049(99)00258-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Warde, Nick. "Does the dose intensity of BEP chemotherapy affect survival?" Nature Reviews Urology 7, no. 9 (2010): 477. http://dx.doi.org/10.1038/nrurol.2010.127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Dodwell, DJ, H. Gurney, and N. Thatcher. "Dose intensity in cancer chemotherapy." British Journal of Cancer 61, no. 6 (1990): 789–94. http://dx.doi.org/10.1038/bjc.1990.178.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Cavaletti, G., L. Marzorati, G. Bogliun, et al. "Cisplatin-lnduced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity." Cancer 69, no. 1 (1992): 203–7. http://dx.doi.org/10.1002/1097-0142(19920101)69:1<203::aid-cncr2820690133>3.0.co;2-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Costabel, U., SD Nathan, L. Lancaster, et al. "Dose modifications and dose intensity during treatment with pirfenidone." Pneumologie 71, S 01 (2017): S1—S125. http://dx.doi.org/10.1055/s-0037-1598499.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Livingston, Robert B. "Dose intensity and high dose therapy. Two different concepts." Cancer 74, S3 (1994): 1177–83. http://dx.doi.org/10.1002/1097-0142(19940801)74:3+<1177::aid-cncr2820741529>3.0.co;2-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Levin, L., and W. M. Hryniuk. "Dose intensity analysis of chemotherapy regimens in ovarian carcinoma." Journal of Clinical Oncology 5, no. 5 (1987): 756–67. http://dx.doi.org/10.1200/jco.1987.5.5.756.

Full text

Abstract:

The relationship between outcome and dose intensity was analyzed for first-line chemotherapy of advanced ovarian cancer using a particular CHAP (cyclophosphamide, hexamethylmelamine, Adriamycin [Adria Laboratories, Columbus, OH], cisplatin) regimen as the standard. Previously described techniques were used to calculate the average dose intensity of regimens containing one, two, three, or all four drugs of CHAP, relative to the standard. The average relative dose intensity, especially the relative dose intensity of cisplatin, correlated significantly with clinical response and with median survi

APA, Harvard, Vancouver, ISO, and other styles

17

Winkelman, Chris, Abdus Sattar, Hasina Momotaz, et al. "Dose of Early Therapeutic Mobility: Does Frequency or Intensity Matter?" Biological Research For Nursing 20, no. 5 (2018): 522–30. http://dx.doi.org/10.1177/1099800418780492.

Full text

Abstract:

Objective: Investigate the feasibility of a nurse-led mobility protocol and compare the effects of once- versus twice-daily episodes of early therapeutic mobility (ETM) and low- versus moderate-intensity ETM on serum biomarkers of inflammation and selected outcomes in critically ill adults. Design: Randomized interventional study with repeated measures and blinded assessment of outcomes. Setting: Four adult intensive care units (ICUs) in two academic medical centers. Subjects: Fifty-four patients with > 48 hr of mechanical ventilation (MV). Intervention: Patients were assigned to once- or t

APA, Harvard, Vancouver, ISO, and other styles

18

Band, Pierre R., Michele Deschamps, and Lucien Israël. "Retinoid Chemoprevention Timing and Dose Intensity." Cancer Investigation 7, no. 2 (1989): 205–10. http://dx.doi.org/10.3109/07357908909038286.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Cohen, M. H. "What determines actual chemotherapy dose intensity?" Journal of Clinical Oncology 8, no. 11 (1990): 1926. http://dx.doi.org/10.1200/jco.1990.8.11.1926.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Hryniuk, W. M., and M. Goodyear. "The calculation of received dose intensity." Journal of Clinical Oncology 8, no. 12 (1990): 1935–37. http://dx.doi.org/10.1200/jco.1990.8.12.1935.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Heller, G., and N. K. Cheung. "Dose-intensity analysis and randomized trials." Journal of Clinical Oncology 9, no. 9 (1991): 1715–16. http://dx.doi.org/10.1200/jco.1991.9.9.1715.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Ozols, Robert F. "Ovarian Cancer: Is Dose Intensity Dead?" Journal of Clinical Oncology 25, no. 27 (2007): 4157–58. http://dx.doi.org/10.1200/jco.2007.12.1723.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Cox, J., D. Ball, C. Belani, et al. "Dose intensity in lung cancer treatment." Lung Cancer 10 (March 1994): S11—S13. http://dx.doi.org/10.1016/0169-5002(94)91661-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Sanchis-Gomar, Fabian, Carmen Fiuza-Luces, and Alejandro Lucia. "Exercise Intensity, Dose, and Cardiovascular Disease." JAMA 315, no. 15 (2016): 1658. http://dx.doi.org/10.1001/jama.2016.0306.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Gregory, S. A., and L. Trümper. "Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?" Annals of Oncology 16, no. 9 (2005): 1413–24. http://dx.doi.org/10.1093/annonc/mdi264.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Simon, R., and E. L. Korn. "Selecting Drug Combinations Based on Total Equivalent Dose (Dose Intensity)." JNCI Journal of the National Cancer Institute 82, no. 18 (1990): 1469–76. http://dx.doi.org/10.1093/jnci/82.18.1469.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Hryniuk, W., E. Frei, and F. A. Wright. "A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity." Journal of Clinical Oncology 16, no. 9 (1998): 3137–47. http://dx.doi.org/10.1200/jco.1998.16.9.3137.

Full text

Abstract:

PURPOSE To construct a single scale for comparing the dose-intensity of all chemotherapy regimens in breast cancer. MATERIALS AND METHODS First-line single-agent trials in metastatic disease were reviewed. The unit dose-intensity (UDI) that was required to produce a 30% complete response plus partial response (CR + PR) rate was determined for each drug. Randomized trials were then analyzed that prospectively tested dose-intensity. The dose-intensities of the drugs in each arm were expressed as fractions of their UDIs and added together. This yielded each arm's summation dose-intensity (SDI), w

APA, Harvard, Vancouver, ISO, and other styles

28

Zelinskiy, A. S., G. A. Yakovlev та D. E. Fil’trov. "Связь мощности дозы гамма-излучения с интенсивностью ливневых осадков". Вестник КРАУНЦ. Физико-математические науки, № 3 (22 листопада 2021): 189–99. http://dx.doi.org/10.26117/2079-6641-2021-36-3-189-199.

Full text

Abstract:

Experimental and theoretical studies of the influence of the intensity, amount and duration of liquid atmospheric precipitation on the formation of γ-background in the surface layer of the atmosphere are presented. It was observed that precipitation causes an increase in the γ-radiation dose rate in the form of bursts. In this case, the total amount of precipitation in an event determines the magnitude of the burst of the dose rate, and the intensity of precipitation determines the rate of increase in the dose rate of γ-radiation. A mathematical model, which establishes a quantitative relation

APA, Harvard, Vancouver, ISO, and other styles

29

Campbell, Patrick G., Ian B. Stewart, Anita C. Sirotic, and Geoffrey M. Minett. "Does exercise intensity affect wellness scores in a dose-like fashion?" European Journal of Sport Science 20, no. 10 (2020): 1395–404. http://dx.doi.org/10.1080/17461391.2019.1710264.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Alghamdi, Mohammed Abdullah, Richard Lee-Ying, Mina Swiha, et al. "The effect of sorafenib (S) starting dose and dose intensity on survival in patients with advanced hepatocellular carcinoma (HCC)." Journal of Clinical Oncology 35, no. 4_suppl (2017): 400. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.400.

Full text

Abstract:

400 Background: The SHARP trial showed that S improves survival in advanced HCC. In clinical practice full dose (FD) of S at 400mg bid can be difficult to tolerate and so a reduced dose (RD) is often required. The purpose of this study was to determine whether starting dose or dose intensity of S affects survival in patients with HCC. Methods: All patients treated with S for HCC in Alberta, Canada from January 2008 to July 2016 were included in this study. Patient demographics, clinical, tumor characteristics, S starting dose and dose intensity were collected and analyzed. Patients were dichot

APA, Harvard, Vancouver, ISO, and other styles

31

Lutfi, Forat, Rohit Boshnoi, Vikas Patel, et al. "Bleeding and Thrombotic Risk in Low Dose Heparin Infusion As Compared to Standard Dose Heparin Infusion." Blood 132, Supplement 1 (2018): 1251. http://dx.doi.org/10.1182/blood-2018-99-110232.

Full text

Abstract:

Abstract Introduction: At our institution, therapeutic use of unfractionated heparin (UFH) is administered by standard (target anti-Xa activity level 0.30 to 0.70 IU/mL) and low intensity (target anti-Xa activity level 0.25 to 0.35 IU/mL) protocols. In patients deemed high-risk for hemorrhage, the low intensity protocol is often employed. However, to date, there has been little study of differences in adverse events, namely hemorrhage, and efficacy between intensity protocols. Furthermore, identifying the effect of patient specific factors (e.g. age, indication for UFH, anticoagulant and antip

APA, Harvard, Vancouver, ISO, and other styles

32

Meyer, R. M., W. M. Hryniuk, and M. D. Goodyear. "The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma." Journal of Clinical Oncology 9, no. 2 (1991): 339–47. http://dx.doi.org/10.1200/jco.1991.9.2.339.

Full text

Abstract:

To determine whether the dose intensity of chemotherapeutic regimens correlates with the complete remission rate in adult patients with advanced-stage intermediate-grade lymphoma, reports of comparative trials of therapy were reviewed. Reports were identified using MEDLINE, through references from review articles, and through review of selected abstracts. Twenty-two studies including 14 randomized and eight cohort trials were analyzed to assess projected dose intensity. Four other studies were analyzed to assess the role of received dose intensity. Dose intensities were calculated using descri

APA, Harvard, Vancouver, ISO, and other styles

33

Leavey, Patrick J., Elpis Mantadakis, and Gerhard Maale. "VARIABILITY IN DOSE INTENSITY OF HIGH-DOSE METHOTREXATE FOR NONMETASTATIC OSTEOSARCOMA." Pediatric Hematology and Oncology 19, no. 7 (2002): 483–89. http://dx.doi.org/10.1080/08880010290097305.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Dembo, A. J. "Time-dose factors in chemotherapy: expanding the concept of dose-intensity." Journal of Clinical Oncology 5, no. 5 (1987): 694–96. http://dx.doi.org/10.1200/jco.1987.5.5.694.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Jensen, Randy L., Merideth M. Wendland, Shyh-Shi Chern, and Dennis C. Shrieve. "NOVALIS INTENSITY-MODULATED RADIOSURGERY." Neurosurgery 62, suppl_5 (2008): A2—A10. http://dx.doi.org/10.1227/01.neu.0000325931.26531.45.

Full text

Abstract:

ABSTRACT OBJECTIVE The Novalis stereotactic radiotherapy system (BrainLAB, Heimstetten, Germany) allows for precise treatment of cranial base tumors with single-fraction radiosurgery. In some cases, however, proximity of the optic nerve and chiasm is a concern. In these cases, intensity-modulated stereotactic radiosurgery (IMRS) can be used to limit the dose to these structures. IMRS planning can be labor intensive, which poses a problem when it is performed on the day of treatment. We describe our methods and results of preprocedure planning for IMRS for patients with lesions in the cavernous

APA, Harvard, Vancouver, ISO, and other styles

36

Smith, Malcolm, Jeffrey Abrams, Edward L. Trimble, and Richard S. Ungerleider. "Dose Intensity of Chemotherapy for Childhood Cancers." Oncologist 1, no. 5 (1996): 293–304. http://dx.doi.org/10.1634/theoncologist.1-5-293.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

de Vries, E. G. E., T. C. Hamilton, M. Lind, J. Dauplat, J. P. Neijt, and R. F. Ozols. "Drug resistance, supportive care and dose intensity." Annals of Oncology 4 (1993): S57—S62. http://dx.doi.org/10.1093/annonc/4.suppl_4.s57.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Thigpen, J. T. "Dose-intensity in ovarian carcinoma: hold, enough?" Journal of Clinical Oncology 15, no. 4 (1997): 1291–93. http://dx.doi.org/10.1200/jco.1997.15.4.1291.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Cohen, M. H. "MOPP dose intensity and survival: flawed analysis." Journal of Clinical Oncology 8, no. 4 (1990): 756–57. http://dx.doi.org/10.1200/jco.1990.8.4.756.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Anderson, J. R., and P. F. Coccia. "Is more better? Dose intensity in neuroblastoma." Journal of Clinical Oncology 9, no. 6 (1991): 902–4. http://dx.doi.org/10.1200/jco.1991.9.6.902.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Eijsvogels, Thijs M. H., and Paul D. Thompson. "Exercise Intensity, Dose, and Cardiovascular Disease—Reply." JAMA 315, no. 15 (2016): 1659. http://dx.doi.org/10.1001/jama.2016.0312.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Alghamdi, Mohammed Abdullah, Richard Lee-Ying, Hao-Wen Sim, et al. "Effect of sorafenib (S) starting dose and dose intensity on survival in patients with hepatocellular carcinoma (HCC): Results from a Canadian multicenter HCC database." Journal of Clinical Oncology 35, no. 15_suppl (2017): 4084. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4084.

Full text

Abstract:

4084 Background: The SHARP trial showed that S improves survival in advanced HCC. Full dose (FD) S at 400mg bid can be difficult to tolerate, so some clinicians begin with a reduced dose (RD) & escalate as tolerated to maximum dose. The purpose of this study was to determine whether starting dose or dose intensity of S affects survival. Methods: All patients treated with S for HCC from 01/2008 to 06/2016 in British Columbia, Alberta, Ontario (Princess Margaret Cancer Centre & Sunnybrook Odette Cancer Centre), were included. Patient demographics, clinical, tumor characteristics, S start

APA, Harvard, Vancouver, ISO, and other styles

43

Stewart, Clinton F. "Pharmacodynamics and Cancer: Practical Aspects of Dose Intensity for Pharmacists." Journal of Pharmacy Practice 4, no. 1 (1991): 11–19. http://dx.doi.org/10.1177/089719009100400103.

Full text

Abstract:

Recent clinical studies have suggested that dose or dose intensity may be a critical factor in achieving an optimal effect from cancer chemotherapy in tumors that are chemosensitive. This article reviews the rationale for the importance of drug dose in cancer chemotherapy and methods of expressing dose intensity. Several clinical studies that provide evidence of the importance of dose intensity are reviewed. The concept of systemic intensity of cancer chemotherapy is discussed. Finally, the practical aspects of dose intensity for the pharmacist are addressed, including dosage calculation, drug

APA, Harvard, Vancouver, ISO, and other styles

44

Ang, P. T., A. U. Buzdar, T. L. Smith, S. Kau, and G. N. Hortobagyi. "Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma." Journal of Clinical Oncology 7, no. 11 (1989): 1677–84. http://dx.doi.org/10.1200/jco.1989.7.11.1677.

Full text

Abstract:

Three hundred thirty-six patients with stage II or stage III breast cancer were treated on an adjuvant protocol containing fluorouracil, doxorubicin, cyclophosphamide, vincristine, and prednisone (FACVP). Depending on the estrogen-receptor (ER) status, the patients were subdivided to receive maintenance chemotherapy with or without tamoxifen. The administered dose intensity of fluorouracil, doxorubicin, and cyclophosphamide (FAC) (mg/m2/wk) relative to the projected dose intensity (based on planned dose) was computed for each patient. The relative dose intensity of the first six cycles of chem

APA, Harvard, Vancouver, ISO, and other styles

45

Murthy, Vedang, Shirley Lewis, Mayur Sawant, Siji N. Paul, Umesh Mahantshetty, and Shyam Kishore Shrivastava. "Incidental Dose to Pelvic Nodal Regions in Prostate-Only Radiotherapy." Technology in Cancer Research & Treatment 16, no. 2 (2016): 211–17. http://dx.doi.org/10.1177/1533034616661447.

Full text

Abstract:

Objectives: Pelvic lymph nodal regions receive an incidental dose from conformal treatment of the prostate. This study was conducted to investigate the doses received by the different pelvic nodal regions with varying techniques used for prostate radiotherapy. Methods and Materials: Twenty patients of high-risk node-negative prostate cancer treated with intensity-modulated radiotherapy to the prostate alone were studied. Replanning was done for intensity-modulated radiotherapy, 3-dimensional conformal treatment, and 2-dimensional conventional radiotherapy with additional delineation of the pel

APA, Harvard, Vancouver, ISO, and other styles

46

Komuro, Ayumi, Sachiko Seo, Nobuo Mochizuki, Yosuke Minami, and Toshikatu Kawasaki. "Impact of Total Dose Intensity and Relative Dose Intensity (RDI) of R-CHOP on Survival in Patients with DLBCL." Blood 132, Supplement 1 (2018): 4218. http://dx.doi.org/10.1182/blood-2018-99-114227.

Full text

Abstract:

Abstract Background: The standard chemotherapy for diffuse large B-cell lymphoma (DLBCL) is CHOP combined with rituximab (R-CHOP). The guidelines (e.g. NCCN or ESMO) recommend six to eight courses of R-CHOP and the optimal number of courses is still unclear. The relative dose intensity (RDI) was proposed as an indicator for both dose intensity and interval. The previous studies have reported the relation between RDI of CHOP or R-CHOP and treatment outcomes. However, little is known about the low threshold of RDI that affects survival and few studies have compared between RDI and total dose of

APA, Harvard, Vancouver, ISO, and other styles

47

LeVasseur, N., and S. K. Chia. "Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?" British Journal of Cancer 117, no. 2 (2017): 157–58. http://dx.doi.org/10.1038/bjc.2017.176.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Lin, Ruihe, Jie Shan, Taize Yuan, and Chaonan Qian. "Dosimetric comparison of intensity-modulated proton radiotherapy versus intensity-modulated photon-based radiotherapy for breast cancer." Visualized Cancer Medicine 2 (2021): 5. http://dx.doi.org/10.1051/vcm/2021002.

Full text

Abstract:

Purpose: This study aims to compare the dosimetric differences in intensity-modulated proton therapy (IMPT) using pencil beam scanning technology and intensity-modulated photon-based radiotherapy (IMRT) in hypofractionated whole-breast irradiation (HF-WBI) and find out the more beneficial technique. Methods and Materials: Eight breast cancer (BC) patients with pathological stage T1 ~ 2N0M0 were immobilized and underwent 4D-CT scanning used deep inspiration breath-hold (DIBH) technology. The IMPT and IMRT plans were designed for each patient. The IMPT plans used two en-face beam angles. IMRT pl

APA, Harvard, Vancouver, ISO, and other styles

49

Meyer, R. M., G. P. Browman, M. L. Samosh, et al. "Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma." Journal of Clinical Oncology 13, no. 9 (1995): 2386–93. http://dx.doi.org/10.1200/jco.1995.13.9.2386.

Full text

Abstract:

PURPOSE To determine whether modifying the standard regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) from full doses given every 3 weeks to one-third doses given weekly (chop) increases the received chemotherapy dose-intensity in elderly patients with advanced-stage intermediate-grade lymphoma. PATIENTS AND METHODS Consenting patients, age > or = 65 years who had acceptable cardiac, renal, and liver function and an Eastern Cooperative Oncology Group (ECOG) performance status less than 4, were stratified by bone marrow and performance status and randomized to rece

APA, Harvard, Vancouver, ISO, and other styles

50

Lewis, Ian J., Simon Weeden, David Machin, Dan Stark, and Alan W. Craft. "Received Dose and Dose-Intensity of Chemotherapy and Outcome in Nonmetastatic Extremity Osteosarcoma." Journal of Clinical Oncology 18, no. 24 (2000): 4028–37. http://dx.doi.org/10.1200/jco.2000.18.24.4028.

Full text

Abstract:

PURPOSE: To examine the relationship between received dose, received dose-intensity (RDI), and survival in patients with osteosarcoma. PATIENTS AND METHODS: Between 1983 and 1993, the European Osteosarcoma Intergroup (EOI) conducted two randomized trials involving patients with high-grade, nonmetastatic, biopsy-proven osteosarcoma of the extremity. These trials shared a common treatment arm of doxorubicin (DOX) 75 mg/m2 and cisplatin (CDDP) 100 mg/m2 planned for six cycles at 3-week intervals. Definitive surgery was scheduled at week 9, after three cycles. Survival time was calculated from 122

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!